Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Neurologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
December 1, 2008
Miami Site May Succeed in Quick Recruitment of a Study Population
Analysis of: Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease | pharmalive.com
Author: GLG Expert Contributor
The CONNECTION study is important in that Dimebon has a mode of action different from all other current treatments. If the results of the phase II study are corroborated, Dimebon may be an important, additional treatment modality.
Daniel WynnNovember 17, 2008
"Tamper-Proof" -- A Significant Gain to Whom??
Analysis of: FDA Asks if Pain Pill Is Tamper-Proof | online.wsj.com
Author: Daniel Wynn, Director, Clinical Research, Consultants In Neurology Ltd.
Abuse resistant long acting narcotics offer benefit as they are less desirable to those who might wish a quick high via snorting, injecting crushed time-release narcotic. Unfortunately, given the higher cost than long acting generics and increased pressure on physicians to prescribe generics, expect...
November 10, 2008
Wild speculation
Analysis of: Autism linked with rainfall in study | www.boston.com
Author: GLG Expert Contributor
I do not believe that any conclusions can be drawn from these data unless they can be confirmed by a larger, more wide ranging population sampling.
November 4, 2008
Vimpat approved ONLY for adjunctive therapy of epilepsy
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
Vimpat was developed to have applicability to other disease processes including neuropathic pain. The limited indication approved for Vimpat suggests the data for other potential uses was not very robust (that had been my observation based on the neuropathic pain studies). Although UCB may be developing...
November 3, 2008
UCB's Vimpat (lacosamide) receives FDA approval
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
FDA has approved lacosamide for add-on therapy of partial onset seizures.  It will be marketed by UCB under the brand name Vimpat.
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
September 2, 2008
Azilect
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease | www.medicalnewstoday.com
Author: GLG Expert Contributor
This is a well conceived study and totally convincing
September 1, 2008
The Devil Is in the Details
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease | www.medicalnewstoday.com
Author: GLG Expert Contributor
This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.
August 6, 2008
Concerns about the Rember Phase 2 data
Analysis of: New Treatment Halts Progress of Alzheimer's Disease | www.abdn.ac.uk
Author: GLG Expert Contributor
While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.
June 26, 2008
Arm Chair Analysis from Monday Morning Quarterbacks provides unrealistic expectations and inappropriate rules
Analysis of: Doctors Say Medication Is Overused in Dementia | www.nytimes.com
Author: GLG Expert Contributor
Medications used for realistic indications and with clinically appropriate symptomatic targets are indicated and provide effectiveness that additional staff cannot offer.  Decision making in health care is too often made by those who do not really provide clinical service but provide arm chair...

Page : 1 2 3 4 5 6 7 8 9 10 Next1 to 10 of 95

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617